Francis Lo Sells 30,593 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 30,593 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $14.08, for a total transaction of $430,749.44. Following the completion of the sale, the insider directly owned 291,374 shares of the company’s stock, valued at $4,102,545.92. The trade was a 9.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Francis Lo also recently made the following trade(s):

• On Thursday, March 5th, Francis Lo sold 38,074 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.09, for a total transaction of $574,536.66.
• On Monday, January 12th, Francis Lo sold 79,590 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.73, for a total transaction of $1,411,130.70.
• On Friday, January 2nd, Francis Lo sold 3,125 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.08, for a total value of $50,250.00.
• On Monday, December 22nd, Francis Lo sold 4,394 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $17.50, for a total value of $76,895.00.
• On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.57, for a total transaction of $1,773,267.30.

Adaptive Biotechnologies Stock Up 5.8%

Shares of ADPT traded up $0.72 during mid-day trading on Friday, reaching $13.17. 3,902,529 shares of the stock traded hands, compared to its average volume of 1,832,300. The stock has a fifty day simple moving average of $16.55 and a 200 day simple moving average of $15.85. Adaptive Biotechnologies Corporation has a 12-month low of $6.68 and a 12-month high of $20.76. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -32.92 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. During the same period in the prior year, the firm earned ($0.23) earnings per share. The business’s quarterly revenue was up 51.0% compared to the same quarter last year. On average, equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price target for the company. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Guggenheim increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Adaptive Biotechnologies in the 4th quarter worth approximately $28,000. Sound Income Strategies LLC acquired a new stake in shares of Adaptive Biotechnologies during the 3rd quarter valued at approximately $30,000. EverSource Wealth Advisors LLC lifted its stake in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the last quarter. Assetmark Inc. lifted its stake in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in Adaptive Biotechnologies in the fourth quarter worth $51,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.